Literature DB >> 2823272

Rearrangement of the p53 gene in human osteogenic sarcomas.

H Masuda1, C Miller, H P Koeffler, H Battifora, M J Cline.   

Abstract

p53 is a 53-kDa nuclear protein that is associated with malignant transformation in several tumor model systems. In a survey of 134 human carcinomas, sarcomas, leukemias, and lymphomas obtained at surgery or from peripheral blood, we found rearrangements of the p53 gene only in osteogenic sarcomas (3 of 6 osteogenic sarcomas examined). Normal tissue from one of these patients had an unrearranged gene, indicating that the genetic abnormality in the tumor was acquired. Two of the sarcomas with rearranged genes expressed levels of p53 protein that were elevated relative to other tumors. Rearranged p53 genes were also found in human osteogenic sarcoma cell lines.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2823272      PMCID: PMC299371          DOI: 10.1073/pnas.84.21.7716

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  19 in total

1.  T antigen is bound to a host protein in SV40-transformed cells.

Authors:  D P Lane; L V Crawford
Journal:  Nature       Date:  1979-03-15       Impact factor: 49.962

2.  Adenovirus E1b-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells.

Authors:  P Sarnow; Y S Ho; J Williams; A J Levine
Journal:  Cell       Date:  1982-02       Impact factor: 41.582

3.  Growth regulation of a cellular tumour antigen, p53, in nontransformed cells.

Authors:  N C Reich; A J Levine
Journal:  Nature       Date:  1984 Mar 8-14       Impact factor: 49.962

4.  Transcriptional activation of an unrearranged and untranslocated c-myc oncogene by translocation of a C lambda locus in Burkitt.

Authors:  C M Croce; W Thierfelder; J Erikson; K Nishikura; J Finan; G M Lenoir; P C Nowell
Journal:  Proc Natl Acad Sci U S A       Date:  1983-11       Impact factor: 11.205

5.  Altered nucleotide sequences of a translocated c-myc gene in Burkitt lymphoma.

Authors:  T H Rabbitts; P H Hamlyn; R Baer
Journal:  Nature       Date:  1983 Dec 22-1984 Jan 4       Impact factor: 49.962

6.  p53 transformation-related protein: detection by monoclonal antibody in mouse and human cells.

Authors:  W G Dippold; G Jay; A B DeLeo; G Khoury; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1981-03       Impact factor: 11.205

7.  Reconstitution of p53 expression in a nonproducer Ab-MuLV-transformed cell line by transfection of a functional p53 gene.

Authors:  D Wolf; N Harris; V Rotter
Journal:  Cell       Date:  1984-08       Impact factor: 41.582

8.  Role of the p53 protein in cell proliferation as studied by microinjection of monoclonal antibodies.

Authors:  W E Mercer; C Avignolo; R Baserga
Journal:  Mol Cell Biol       Date:  1984-02       Impact factor: 4.272

9.  Post-translational regulation of the 54K cellular tumor antigen in normal and transformed cells.

Authors:  M Oren; W Maltzman; A J Levine
Journal:  Mol Cell Biol       Date:  1981-02       Impact factor: 4.272

10.  Detection of a common feature in several human tumor cell lines--a 53,000-dalton protein.

Authors:  L V Crawford; D C Pim; E G Gurney; P Goodfellow; J Taylor-Papadimitriou
Journal:  Proc Natl Acad Sci U S A       Date:  1981-01       Impact factor: 11.205

View more
  145 in total

1.  Evidence that replication of the antitumor adenovirus ONYX-015 is not controlled by the p53 and p14(ARF) tumor suppressor genes.

Authors:  Sara J Edwards; Brett R Dix; Colleen J Myers; Deirdre Dobson-Le; Lily Huschtscha; Merilyn Hibma; Janice Royds; Antony W Braithwaite
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

2.  p53 functions as a cell cycle control protein in osteosarcomas.

Authors:  L Diller; J Kassel; C E Nelson; M A Gryka; G Litwak; M Gebhardt; B Bressac; M Ozturk; S J Baker; B Vogelstein
Journal:  Mol Cell Biol       Date:  1990-11       Impact factor: 4.272

3.  p53 expression in lymphatic malignancies.

Authors:  Y Soini; P Pääkkö; M Alavaikko; K Vähäkangas
Journal:  J Clin Pathol       Date:  1992-11       Impact factor: 3.411

4.  The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia.

Authors:  H Ahuja; M Bar-Eli; Z Arlin; S Advani; S L Allen; J Goldman; D Snyder; A Foti; M Cline
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

5.  Nm23-H1 can induce cell cycle arrest and apoptosis in B cells.

Authors:  Tathagata Choudhuri; Masanao Murakami; Rajeev Kaul; Sushil K Sahu; Suchitra Mohanty; Subhash C Verma; Pankaj Kumar; Erle S Robertson
Journal:  Cancer Biol Ther       Date:  2010-06-11       Impact factor: 4.742

6.  The history of p53. A perfect example of the drawbacks of scientific paradigms.

Authors:  Thierry Soussi
Journal:  EMBO Rep       Date:  2010-10-08       Impact factor: 8.807

7.  Characterization of the human p53 gene promoter.

Authors:  S P Tuck; L Crawford
Journal:  Mol Cell Biol       Date:  1989-05       Impact factor: 4.272

8.  Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53.

Authors:  C Kunz; S Pebler; J Otte; D von der Ahe
Journal:  Nucleic Acids Res       Date:  1995-09-25       Impact factor: 16.971

9.  P53 mutation in acute T cell lymphoblastic leukemia is of somatic origin and is stable during establishment of T cell acute lymphoblastic leukemia cell lines.

Authors:  J Yeargin; J Cheng; A L Yu; R Gjerset; M Bogart; M Haas
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

10.  Human cytomegalovirus IE1-72 protein interacts with p53 and inhibits p53-dependent transactivation by a mechanism different from that of IE2-86 protein.

Authors:  Eung-Soo Hwang; Zhigang Zhang; Haobin Cai; David Y Huang; Shu-Mei Huong; Chang-Yong Cha; Eng-Shang Huang
Journal:  J Virol       Date:  2009-09-23       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.